Please login to the form below

belimumab

This page shows the latest belimumab news and features for those working in and with pharma, biotech and healthcare.

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

GSK’s Benlysta (belimumab) has been given Orphan Drug Designation (ODD) by the US Food and Drug Administration for the potential treatment of systemic sclerosis (SSc), the company announced. ... The company said in a statement: ‘With limited

Latest news

Biogen scores mid-stage trial win for lupus drug BIIB059

It has very few treatment options – the last treatment to be approved by the FDA was GlaxoSmithKline’s Benlysta (belimumab) back in 2011, which ended a 50-year drought in new
Second TULIP trial resurrects AZ’s lupus drug anifrolumab

SRI4 measurements are tried and tested from a regulatory perspective, having been used to back the US approval of GlaxoSmithKline’s Benlysta(belimumab) in 2011.
Is GSK planning to exit the respiratory business?

It is however growing at a much faster rate; respiratory grew 3%, HIV was up 11% and immuno-inflammation – led by lupus drug Benlysta (belimumab) – rose 28%.
GSK closes in on EU approval for triple COPD therapy

The CHMP also delivered more good news to GSK by recommending approval of the company's subcutaneous pen-injector of Benlysta (belimumab), providing a more patient-friendly alternative to the current
GSK and AZ drugs impress in lupus trials

GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product - which was approved as in one-hour infusion formulation for SLE in 2011, ... placebo. "On the basis of these data, we expect to progress

More from news
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Building a business that is lean and specialised

The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.
Pharma deals during July 2012

These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

No results were found

PMHub

Add my company

Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications: Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers: Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs: It’s not a question of ‘if,’ it’s a question of ‘when.’...

Email:
Password:

Please login to the form below

belimumab

Subscribe to our email news alerts

Quick links